1. Introduction {#sec1-genes-11-00024}
===============

Currently, the molecular diagnosis of rare genetic diseases with clinical and genetic heterogeneity, such as inherited retinal dystrophies (IRD) \[[@B1-genes-11-00024],[@B2-genes-11-00024]\], has become more accessible and accurate with the use of next-generation sequencing \[[@B3-genes-11-00024],[@B4-genes-11-00024],[@B5-genes-11-00024],[@B6-genes-11-00024]\]. However, the interpretation of variants found in these molecular tests is still a major challenge for all professionals involved in molecular diagnosis and genetic counseling. Typically, novel variants have never been previously described and their impacts on the gene or protein are unknown; therefore, they are classified as variants of uncertain significance (VUS), rendering the genetic diagnosis inconclusive.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines \[[@B7-genes-11-00024]\] suggest that genetic variants are classified on a five-level scale: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. For this classification to be made, different criteria must be considered together for an assessment of the likelihood of any variant being pathogenic or benign.

Briefly, the criteria for classifying the pathogenicity of variants are: (i) variants that have been reported to cause disease in the literature, (ii) variants that lead to loss of protein function, (iii) variants that are absent or infrequent in genetic variant databases, (iv) variants not described, but present in other affected patients, and (v) variants that have not been reported in the literature, but are predicted by in silico analysis as likely damaging. Further description of variant classification guidelines is detailed in the ACMG/AMP guidelines \[[@B7-genes-11-00024]\].

Several pathogenic variants have already been described in the *RPE65* gene \[[@B8-genes-11-00024],[@B9-genes-11-00024],[@B10-genes-11-00024]\] which lead to childhood retinal dystrophy, ranging from Leber congenital amaurosis (LCA) to early-onset retinal dystrophy (EORD). These diseases are the earliest and most severe inherited retinal dystrophies \[[@B11-genes-11-00024],[@B12-genes-11-00024]\]. Appropriate pathogenicity classification of novel variants is relevant not only to the conclusion of molecular diagnosis and genetic counseling but also to medical management of the condition. Currently, a gene therapy treatment is available for *RPE65* (LUXTURNA^®^-voretigene neparvovec-rzyl). For these reasons, this paper aims to reclassify two of the most frequent *RPE65* missense variants of uncertain significance found in Brazilian families.

2. Materials and Methods {#sec2-genes-11-00024}
========================

This retrospective cross-sectional study was approved by the Ethics Committee in Research of Universidade Federal de São Paulo (CEP: 0415/2016). Written informed consent for the use of personal medical data for scientific purposes and publication was obtained from all patients. In addition, this study was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its subsequent amendments.

2.1. Subjects {#sec2dot1-genes-11-00024}
-------------

Five hundred and fifty-six retinopathy gene panels from IRD patients (513 families), recruited from five specialized services in inherited retinal dystrophy in Brazil (Universidade Federal de São Paulo, Instituto de Genética Ocular, INRET Clínica e Centro de Pesquisa, Centro Oftalmológico de Minas Gerais, and Instituto de Olhos Carioca), were reviewed in order to find patients with c.247T\>C (p.Phe83Leu) or c.560G\>A (p.Gly187Glu) variants in *RPE65* (NM_000329.3). All genetic data analyzed were based on sequencing from a 224-gene retinopathy panel ([Supplementary](#app1-genes-11-00024){ref-type="app"}). The p.Phe83Leu variant was found exclusively in five homozygous patients from four families, while p.Gly187Glu was present only in seven homozygous patients from three families. Neither p.Phe83Leu nor p.Gly187Glu was found in other IRD probands from our sample. Medical and family histories of these 12 patients were collected. Most patients were ophthalmologically evaluated. Clinical diagnosis was based on signs/symptoms, ophthalmologic features, and age of onset.

These two variants were chosen for further analysis because among 513 Brazilian families analyzed with IRD history, 15 potentially disease-causing variants of *RPE65* were found. Five of them were missenses and considered pathogenic in the literature: p.Leu22Pro \[[@B13-genes-11-00024],[@B14-genes-11-00024],[@B15-genes-11-00024],[@B16-genes-11-00024],[@B17-genes-11-00024],[@B18-genes-11-00024]\], p.Arg91Pro \[[@B19-genes-11-00024]\], p.Arg91Gln \[[@B16-genes-11-00024],[@B17-genes-11-00024],[@B20-genes-11-00024],[@B21-genes-11-00024],[@B22-genes-11-00024]\], p.Leu341Ser \[[@B22-genes-11-00024],[@B23-genes-11-00024],[@B24-genes-11-00024]\], and p.Gly528Val \[[@B20-genes-11-00024],[@B25-genes-11-00024]\]. Only p.Phe83Leu and p.Gly187Glu were variants of uncertain significance. Additionally, these variants were present in more than one family and in at least one family with more than one affected member. Outside of these two variants, no additional missense biallelic variants were found among the 513 analyzed families.

2.2. Family Segregation {#sec2dot2-genes-11-00024}
-----------------------

In order to verify if the disease segregated only with homozygous variants, segregation analysis was performed in all available probands' informative relatives ([Figure 1](#genes-11-00024-f001){ref-type="fig"}A). Sanger sequencing was performed using genomic DNA from whole blood cells and specific oligonucleotide primers flanking exons 4 and 5 to detect p.Phe83Leu (5′-GGC CAT TCT AAG CTC CAC ATG-3′ and 5′-GCA GGA AAG CAT CAT AGA CAG AG-3′), and flanking exon 6 to detect p.Gly187Glu (5′-TCC AGA TTC AGA CAC ATG AGG-3′ and 5′-TAG GGT AGG GAT GAG GGC AG-3′).

2.3. Variant Analysis {#sec2dot3-genes-11-00024}
---------------------

The evaluation of the p.Phe83Leu and p.Gly187Glu variants in *RPE65* was made according to ACMG standardization \[[@B7-genes-11-00024]\]. For proper classification of pathogenicity, population databases (The Genome Aggregation Database (gnomAD) \[[@B26-genes-11-00024]\], The Exome Aggregation Consortium (ExAC) \[[@B27-genes-11-00024]\], The NHLBI GO Exome Sequencing Project (ESP) \[[@B28-genes-11-00024]\], the 1000 Genomes Project \[[@B29-genes-11-00024]\], Online Archive of Brazilian Mutations (ABraOM) \[[@B30-genes-11-00024]\]) and human variation and phenotype databases (ClinVar) \[[@B8-genes-11-00024]\], The Universal Protein Resource (UniProt) \[[@B9-genes-11-00024]\], and The Human Gene Mutation Database (HGMD^®^) \[[@B10-genes-11-00024]\]) were consulted. In addition, variants were evaluated by multiple in silico predictive algorithms (Polymorphism Phenotyping v2 (PolyPhen2) \[[@B31-genes-11-00024]\], Sorting Intolerant From Tolerant (SIFT) \[[@B32-genes-11-00024]\], Deleterious Annotation of genetic variants using Neural Networks (DANN) \[[@B33-genes-11-00024]\], Protein Variation Effect Analyzer (PROVEAN) \[[@B34-genes-11-00024]\], the Likelihood Ratio Test (LRT) \[[@B35-genes-11-00024]\], MutationTaster \[[@B36-genes-11-00024]\], MutationAssessor \[[@B37-genes-11-00024]\], Functional Analysis through Hidden Markov Models (FATHMM) \[[@B38-genes-11-00024]\], Functional Analysis through Hidden Markov Models---Multiple Kernel Learning (FATHMM-MKL) \[[@B39-genes-11-00024]\], Mendelian Clinically Applicable Pathogenicity (M-CAP) \[[@B40-genes-11-00024]\], Combined Annotation-Dependent Depletion (CADD) \[[@B41-genes-11-00024]\], Ensembl Meta-analytic Support Vector Machine (MetaSVM) \[[@B42-genes-11-00024]\], Ensembl Meta Logistic Regression (MetaLR) \[[@B43-genes-11-00024]\], Phylogenetic *P*-values to multiple alignments of 20 species (PhyloP 20way) \[[@B44-genes-11-00024]\], Phylogenetic *P*-values to multiple alignments of 100 species (PhyloP 100way) \[[@B44-genes-11-00024]\], and The Genomic Evolutionary Rate Profiling---Rejected Substitution (GERP RS) \[[@B45-genes-11-00024]\]) that analyze amino acid conservation and/or the putative impact of variants on protein structure or functionality. In order to assess the association between childhood retinal dystrophies and *RPE65* variants, the odds ratios (OR) of LCA/EORD with Haldane--Anscombe correction and 97.5% confidence intervals (corrected by Bonferroni multiple-comparison correction) were calculated using IBM SPSS Statistics. An OR ≥ 3, with a confidence interval which did not include the number 1, was considered as a positive association between the found variant and the disease.

3. Results and Discussion {#sec3-genes-11-00024}
=========================

3.1. Pathogenicity Classification of RPE65 Variants c.247T\>C (p.Phe83Leu) and c.560G\>A (p.Gly187Glu) According to the Current Literature and Databases {#sec3dot1-genes-11-00024}
--------------------------------------------------------------------------------------------------------------------------------------------------------

Missense variants related to recessive diseases should be classified for pathogenicity following certain criteria/evidence established by the ACMG/AMP. Each piece of evidence is weighted as very strong, strong, moderate, or supporting \[[@B7-genes-11-00024]\]. Some criteria related to dominant disease as well as null variants were not addressed here, because the genic variants under consideration are of the missense type and the gene is related only to recessive diseases. Another criterion not discussed was whether the phenotype is highly specific for a disorder with a single disease-causing gene because inherited retinal dystrophies have significant genetic heterogeneity and relevant clinical overlap.

Two studies have already reported these variants, but they did not confirm or discuss the pathogenicity of c.247T\>C (p.Phe83Leu) or c.560G\>A (p.Gly187Glu) \[[@B22-genes-11-00024],[@B46-genes-11-00024]\]; moreover, these two reported cases are Brazilian and are included in this study (family B and E probands). Based on current knowledge of these two *RPE65* variants, no strong evidence has been identified, as there are no previously reported mutations which, regardless of nucleotide change, result in p.Phe83Leu or p.Gly187Glu, and no functional studies showing that these variants cause deleterious effects.

Two other moderate criteria that evaluate the position where the new missense mutation occurs were also not included: (i) outside of these two variants already reported \[[@B22-genes-11-00024],[@B46-genes-11-00024]\], no other damaging missense variant in the amino acid residue Phe83 or Gly187 has been reported before and, (ii) the protein region where both variants occur is neither a mutational hot spot nor a well-established functional domain.

Both variants in this study have already been associated with rare recessive retinal dystrophies, each of which was identified in only one homozygous patient \[[@B22-genes-11-00024],[@B46-genes-11-00024]\]. Therefore, the criterion regarding the identification of evaluated variants in trans with known pathogenic mutations was not met (ACMG/AMP pathogenic moderate level of evidence). The variants evaluated here are rare: c.247T\>C; p.Phe83Leu is a novel variant not found in any of the five population databases queried ([Table 1](#genes-11-00024-t001){ref-type="table"}), and c.560G\>A; p.Gly187Glu was only seen twice (two heterozygous individuals) out of more than 125,000 individuals analyzed ([Table 1](#genes-11-00024-t001){ref-type="table"}) (ACMG/AMP moderate criterion). Based on the current literature and their extremely low frequencies, it cannot be claimed that these variants were significantly more frequent in affected people than either in the controls or as was observed in many unrelated patients (ACMG/AMP pathogenic strong/moderate criterion), nor that they segregated with disease in several affected family members (ACMG/AMP supporting evidence criterion).

The ClinVar \[[@B8-genes-11-00024]\] and UniProt \[[@B9-genes-11-00024]\] databases show that there are 69 pathogenic variants in the *RPE65* gene, of which 52 are missenses. While HGMD \[[@B10-genes-11-00024]\] lists 191 *RPE65* disease-causing mutations, 103 of these are missense variants, which suggests that missense changes are a common cause of *RPE65*-associated IRD (ACMG/AMP supporting evidence criterion). In addition, 15 out of 16 in silico prediction tools support that the amino acids of both variants are conserved and/or that their changes would negatively impact protein function ([Table 2](#genes-11-00024-t002){ref-type="table"}) (ACMG/AMP supporting evidence criterion).

Initially, the c.247T\>C; p.Phe83Leu and c.560G\>A; p.Gly187Glu variants met only three pieces of ACMG/AMP pathogenic evidence: (i) absence or low frequency in the population (ACMG/AMP pathogenic moderate criterion PM2), (ii) *RPE65* having many pathogenic missense variants (ACMG/AMP supporting level of evidence PP2), and (iii) several lines of computational prediction evidence supporting them as disease-causing mutations (ACMG/AMP supporting criterion PP3). Based on the combination of these three criteria, these variants were classified as variants of uncertain significance.

3.2. Evaluation of the RPE65 Variants p.Phe83Leu and p.Gly187Glu in Brazilian Families with Inherited Retinal Dystrophies {#sec3dot2-genes-11-00024}
-------------------------------------------------------------------------------------------------------------------------

The p.Phe83Leu alleles were found in five homozygous LCA patients from four unrelated families (families A to D; [Figure 1](#genes-11-00024-f001){ref-type="fig"}A), while the p.Gly187Glu alleles were identified in seven LCA/EORD homozygous patients from three different families. Some of these families had other affected individuals who were not accessible for genetic testing (families E to G; [Figure 1](#genes-11-00024-f001){ref-type="fig"}A). Segregation analysis in several family members showed that retinal dystrophy segregates together with the homozygous genotype of these two variants. All heterozygous or wild-type individuals for their respective family mutations were unaffected ([Figure 1](#genes-11-00024-f001){ref-type="fig"}A).

All affected individuals with the genotype of homozygous p.Phe83Leu were diagnosed with LCA. Nystagmus was a common clinical finding, and the onset of the first signs and symptoms, such as low vision and/or nystagmus, occurred before 1 year of age ([Table 3](#genes-11-00024-t003){ref-type="table"}). The clinical diagnosis for p.Gly187Glu patients was mostly EORD, and nystagmus was not reported by all patients. The typical features of the *RPE65* fundus \[[@B22-genes-11-00024]\] found in these patients were pigmentary changes (granular appearance of retinal pigment epithelium and peripheral bone spicule pigmentation) that progress to areas of atrophy. In addition, in more advanced cases, macular atrophic changes were observed ([Figure 1](#genes-11-00024-f001){ref-type="fig"}B,C), and some patients also had vessel attenuation ([Figure 1](#genes-11-00024-f001){ref-type="fig"}C).

The allelic frequency of the variants p.Phe83Leu and p.Gly187Glu in Brazilian probands with inherited retinal dystrophies was 0.0078 (8 of 1026 alleles) and 0.0058 (6 of 1026 alleles), respectively ([Table 4](#genes-11-00024-t004){ref-type="table"}). No heterozygous or compound heterozygous variants were identified in these samples, which means that p.Phe83Leu and p.Gly187Glu variants were only found in the cases exposed in this study.

[Table 5](#genes-11-00024-t005){ref-type="table"} presents the data used to compare the prevalence of homozygous variants in patients with LCA/EORD and other IRD patients. The calculated odds ratios of LCA/EORD (OR~Phe83Leu~ = 42.285; 97.5% CI~Phe83Leu~ = (1.482, 1206.268) and OR~Gly187Glu~ = 32.525; 97.5% CI~Gly187Glu~ = (1.088, 972.642)) indicate a positive association between LCA/EORD and homozygous p.Phe83Leu and p.Gly187Glu variants, suggesting a higher prevalence of these variants in individuals with LCA/EORD than with other subtypes of IRD.

These findings in Brazilian patients suggest the homozygous variants, p.Phe83Leu and p.Gly187Glu, apparently segregate together with childhood retinal dystrophy within families (ACMG/AMP pathogenic supporting criterion PP1). In addition, these variants were observed in several unrelated patients with similar phenotypes and were positively associated with LCA/EORD, presenting odds ratios greater than 3 and 97.5% confidence intervals not including 1.00. Therefore, the prevalence of p.Phe83Leu and p.Gly187Glu in individuals affected by LCA/EORD can be considered significantly higher compared with other inherited retinal dystrophies (ACMG/AMP pathogenic strong level of evidence PS4).

This study adds two more pieces of evidence of pathogenicity in the evaluation of the *RPE65* variants p.Phe83Leu and p.Gly187Glu, one supporting (PP1) and one strong (PS4). Thus, these variants meet five ACMG/AMP pathogenicity criteria, one strong (PS4), one moderate (PM2) and three supporting (PP1, PP2, and PP3), which allows us to reclassify them as likely pathogenic \[[@B7-genes-11-00024]\]. Some criteria proposed by the ACMG/AMP are for cases of dominant diseases, variants with premature stop codon formation, or for syndromic cases. Thus, little evidence of pathogenicity remained to be evaluated in this study.

Confirmation of one more additional criterion, presented below, would change the classification to pathogenic. The presence of compound heterozygote affected individuals, with variants in trans where one variant is known to be pathogenic, would allow us to accept the moderate criterion PM3. The PP1 criteria could be improved from a supporting criterion to either moderate or strong if more families of different ethnicities present the same variant. The addition of either of these criteria would lift the final classification from likely pathogenic to pathogenic.

The PP4 criterion, accounting for the use of phenotype to support the variant, could not be fully met because the ACMG/AMP guidelines specify four criteria, in which only three of them are met: (i) the clinical sensitivity of testing to diagnose affected individuals is high; (ii) the gene is not subject to substantial benign variation---according to the Varsome database \[[@B47-genes-11-00024]\] only eight variants are classified as benign out of 93 present in their database (version November 28, 2019); and (iii) family history is consistent with the mode of inheritance of the disorder---in this sample group all affected individuals have homozygous variants and all heterozygous carriers are unaffected. Criteria (iv) could not be utilized because LCA and EORD are not syndromic.

The ACMG/AMP guidelines are a useful tool for increasing the concordance of variant interpretations. However, it is noted that some criteria proposed by these guidelines are too restrictive (e.g., PP4), questionable (e.g., PM3 and PP5), or the way of applying it is not very clear (e.g., PP1). Thus, the identification of a rare variant exclusively in individuals affected by the same disease from different families is a relevant criterion to evaluate the pathogenicity of the variant.

Initial classification of these two homozygous variants determined they were variants of uncertain significance. However, including a systematic review of mutations present in a population sample allowed for their reclassification to likely pathogenic. Identifying variants with a greater potential for pathogenicity enables researchers to prioritize those variants for further evaluation and exploration by in vivo or in vitro functional studies.

Several animal models for inherited retinal dystrophy used for in vivo functional studies have been reported, including dog and rodent models \[[@B48-genes-11-00024],[@B49-genes-11-00024],[@B50-genes-11-00024],[@B51-genes-11-00024]\]. Animals with *RPE65* variants are able to develop human-like retinopathies, allowing investigators to evaluate the effect of these variants during retinal development and even in advanced stages of animal life in order to establish a more robust genotype--phenotype correlation \[[@B52-genes-11-00024],[@B53-genes-11-00024],[@B54-genes-11-00024],[@B55-genes-11-00024],[@B56-genes-11-00024],[@B57-genes-11-00024]\]. Studies have shown that *RPE65* mutations can modulate disease phenotypes, and variants in other genes can also influence *RPE65*-related phenotype \[[@B58-genes-11-00024],[@B59-genes-11-00024],[@B60-genes-11-00024],[@B61-genes-11-00024]\]. In this respect, animal models are also informative as they allow the creation of specific genotypes to assess the effect of variant combinations on phenotype severity. The evaluation of gene therapy treatments in animal models is invaluable as it allows for the evaluation of potential outcomes or complications of such therapies \[[@B62-genes-11-00024],[@B63-genes-11-00024],[@B64-genes-11-00024],[@B65-genes-11-00024],[@B66-genes-11-00024],[@B67-genes-11-00024]\].

Despite the many advantages of functional studies with animal models, this strategy is often expensive, laborious, and can take significant time before the first genetically modified organisms can be evaluated. To overcome these obstacles, in vitro studies evaluating the correct production and expression of the RPE65 protein (e.g., immunoblot, RT-qPCR, and RNA-sequencing), as well as its enzymatic activity, are advantageous. The evaluation of isomerhydrolase activity of *RPE65* can be measured using iPS-derived retinal pigment epithelium (RPE) cells from patients, hES-derived RPE cells modified by site-directed mutagenesis, or transfected cells with a mutated *RPE65* expression vector \[[@B14-genes-11-00024],[@B25-genes-11-00024],[@B68-genes-11-00024],[@B69-genes-11-00024]\].

Recently, Li and colleagues (2019) presented new perspectives for personalized functional studies utilizing retinal organoids containing RPE and photoreceptor cells derived from human-induced pluripotent stem cells \[[@B69-genes-11-00024]\]. Despite the need for further studies to evaluate the ability of these organoids to mimic the phenotype and molecular aspects of the retina, the generation of these organoids can still enhance the study of cell replacement therapies.

In regards to gene therapy, Yang et al. (2019) also discussed the need for in vitro analysis to verify the pathogenicity of VUS variants prior to the administration of voretigene neparvovec-rzyl, thus avoiding treatments of false-positive individuals \[[@B70-genes-11-00024]\]. They also highlighted the importance of this process, which will allow clinicians to choose relevant candidates for gene therapy.

4. Conclusions {#sec4-genes-11-00024}
==============

These study findings suggest that the molecular diagnosis of patients with p.Phe83Leu and p.Gly187Glu variants, in homozygosis or in trans with another pathogenic variant in the *RPE65* gene, should be considered likely pathogenic. Therefore, these patients are possible candidates for gene therapy treatments. This approach of revisiting the variant classification status based on descriptions of new affected individuals could help to improve variant classification and consequently have an impact on clinical practice and molecular diagnosis.
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![Pedigrees and clinical findings of *RPE65* patients. (**A**) Pedigrees of c.247T\>C (p.Phe83Leu) families with LCA (families A to D) and c.560G\>A (p.Gly187Glu) families with LCA/EORD (families E to G). All probands and some affected relatives genotyped are homozygotes. (**B**) Color fundus photograph of a proband at age 37 from family B. (**C**) Color fundus photograph of a proband at age 35 from family F. N/A---data not available.](genes-11-00024-g001){#genes-11-00024-f001}

genes-11-00024-t001_Table 1

###### 

Evaluation of p.Phe83Leu and p.Gly187Glu in genetics databases.

                                                c.247T\>C; p.Phe83Leu                                c.560G\>A; p.Gly187Glu
  --------------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  *Population Genetics Databases*                                                                    
  gnomAD total                                  No data                                              2 in 251,106 alleles
  ExAC total                                    No data                                              1 in 120,880 alleles
  ESP                                           No data                                              No data
  1000 Genomes                                  No data                                              No data
  ABraOM                                        No data                                              No data
  *Human Variations and Phenotypes Databases*                                                        
  ClinVar                                       Not reported                                         Not reported
  UniProt                                       Not reported                                         Not reported
  HGMD                                          Disease-Causing Mutation \[[@B22-genes-11-00024]\]   Disease-Causing Mutation \[[@B46-genes-11-00024]\]

genes-11-00024-t002_Table 2

###### 

Evaluation of p.Phe83Leu and p.Gly187Glu by 16 predictors.

                                                      Prediction or Score     
  --------------------------------------------------- ----------------------- ------------------------
  In Silico Prediction Tool                           c.247T\>C; p.Phe83Leu   c.560G\>A; p.Gly187Glu
  PolyPhen2                                           Possibly damaging       Probably damaging
  SIFT                                                Damaging                Damaging
  DANN (max. damaging score 1)                        0.9955                  0.9979
  PROVEAN                                             Damaging                Damaging
  LRT                                                 Deleterious             Deleterious
  MutationTaster                                      Disease-causing         Disease-causing
  MutationAssessor                                    Medium impact           Medium impact
  FATHMM \[[@B38-genes-11-00024]\]                    Damaging                Damaging
  FATHMM-MKL                                          Damaging                Damaging
  M-CAP                                               Damaging                Damaging
  CADD (\>20 more likely the SNV is damaging)         24.9                    32
  MetaSVM                                             Damaging                Damaging
  MetaLR                                              Damaging                Damaging
  PhyloP 20way (max. conservation score 1.199000)     1.199000                0.807000
  PhyloP 100way (max. conservation score 10.003000)   8.735000                7.461000
  GERP RS (max. conservation score 6.17)              5.03                    5.54

genes-11-00024-t003_Table 3

###### 

Clinical data of genotyped affected patients with p.Phe83Leu or p.Gly187Glu *RPE65* variant.

  Family   Patient   Diagnosis     Age of Onset    Current Age      Visual Acuity (OD;OE)               Other Findings
  -------- --------- ------------- --------------- ---------------- ----------------------------------- -----------------------------------
  A        II:1      LCA           since birth     27 years         20/1600; 20/800                     Nystagmus, Light-seeking behavior
  II:4     LCA       since birth   20 years        20/200; 20/200   Nystagmus, Light-seeking behavior   
  B        II:1      LCA           before 1 year   37 years         20/800; 20/1600                     Nystagmus
  C        II:1      LCA           before 1 year   49 years         Light Perception                    Nystagmus, Optic nerve drusen
  D        II:1      LCA           before 1 year   13 years         N/A                                 Nystagmus
  E        II:2      EORD          N/A             39 years         20/400; 20/400                      Nystagmus
  II:4     EORD      N/A           34 years        N/A              N/A                                 
  F        II:1      LCA           since birth     35 years         20/60; 20/60                        No nystagmus
  II:8     LCA       since birth   37 years        20/400; 20/200   No nystagmus                        
  G        II:7      EORD          N/A             54 years         20/800; 20/500                      N/A
  II:8     EORD      7 years       51 years        Hand Movement    N/A                                 
  II:23    EORD      N/A           71 years        20/500; 20/500   N/A                                 

LCA---Leber congenital amaurosis; EORD---early-onset retinal dystrophy; N/A---not available.

genes-11-00024-t004_Table 4

###### 

Allele frequency of *RPE65* variants among Brazilian IRD patients (n = 513 probands).

  Nucleotide Change \*   Consequence   Brazilian IRD Patients                   
  ---------------------- ------------- ------------------------ ------ -------- ---
  c.247T\>C              p.Phe83Leu    8                        1026   0.0078   4
  c.560G\>A              p.Gly187Glu   6                        1026   0.0058   3

\* based on transcript NM_000329.3; IRD---inherited retinal dystrophy.

genes-11-00024-t005_Table 5

###### 

Cross-sectional study with 556 Brazilian IRD patients from 513 families.

  Genotype                               LCA/EORD (*n* = 93)   Other IRD (*n* = 420)   OR \* (97.5%CI) †
  -------------------------------------- --------------------- ----------------------- -------------------------
  c.247T\>C;p.Phe83Leu Homozygous        4                     0                       42.285 (1.482--206.268)
  c.247T\>C;p.Phe83Leu Non-Homozygous    89                    420                     
  c.560G\>A;p.Gly187Glu Homozygous       3                     0                       32.525 (1.088--972.642)
  c.560G\>A;p.Gly187Glu Non-Homozygous   90                    420                     

\* OR---odds ratio with Haldane--Anscombe correction; † confidence interval of 97.5% with Bonferroni multiple-comparison correction; LCA---Leber congenital amaurosis; EORD---early-onset retinal dystrophy; IRD---inherited retinal dystrophy.
